Clinical Trial Update: Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial assessing trigriluzole in combination with nivolumab and pembrolizumab for various metastatic or unresectable solid tumors and lymphomas; study co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Classical Hodgkin Lymphoma
• Head and Neck Squamous Cell Carcinoma
• Lymphoma
• Malignant Solid Neoplasm
• Melanoma
• Non-small Cell Lung Cancer
• Renal Cell Cancer
• Renal Cell Carcinoma
• Skin Melanoma
• Stage Iiia Non-small Cell Lung Cancer
• Stage Iiia Skin Melanoma
• Stage Iiib Non-small Cell Lung Cancer
• Stage Iiib Skin Melanoma
• Stage Iiic Skin Melanoma
• Stage Iva Bladder Cancer
• Stage Ivb Bladder Cancer
• Unresectable Head and Neck Squamous Cell Carcinoma
• Unresectable Solid Neoplasm

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Trigriluzole (trigriluzole)
• nivolumab (nivolumab)

Snippet

Sponsor: Rutgers, The State University of New Jersey | Conditions: Lymphoma, Metastatic Malignant Solid Neoplasm | Phase 1 | Status: COMPLETED | Results posted: 2023-12-06